Immix Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
08/08/2025 23:03
Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report results on August 11 (estimated) for the period ending September 30 2025 LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 16 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts had risen by about 23.8% in the last three months. Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00, about 65.9% above its last closing price of $2.39 This summary was machine generated August 8 at 22:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary